[Medical significance of endothelial glycocalyx. Part 2: Its role in vascular diseases and in diabetic complications].
Endothelial glycocalyx is a layer composed by glycosaminoglycans, proteoglycans and glycoproteins attached to the vascular endothelial luminal surface. Shredding of glycocalyx appears as an essential initial step in the pathophysiology of atherosclerosis and microangiopathic complications of diabetes mellitus, as well as in chronic venous disease. Atherosclerosis risk factors, as hypercholesterolemia (LDL), hyperglycemia, inflammation, salt excess and altered shear stress can damage glycocalyx. This lead to endothelial dysfunction and allows LDL and leukocytes to filtrate to the subendothelial space initiating atheroma plaque formation. Degradation of glycocalyx in diabetes mellitus is mainly due to oxidative stress and enables protein filtration (albuminuria) and endothelial disorder of microangiopathy. Chronic venous hypertension brings to altered shears stress which results in shredded glycocalyx, this allows leukocytes to migrate into venous wall and initiate inflammation leading to morphologic and functional venous changes of the chronic venous disease. Treatment with glycosaminoglycans (sulodexide) prevents or recovers the damaged glycocalyx and several of its consequences. This drug improves chronic venous disease and promotes healing of chronic venous ulcers. It has also been useful in peripheral arterial obstructive disease and in diabetic nephropathy with albuminuria.
Departamento de Medicina Interna, Hospital Médica Sur, México D.F., México. Electronic address: AFrati@alfawassermann.com.
Alberto C
AC
Frati Munari
D050197:Atherosclerosis / Q000209:etiology / Q000473:pathology; D002908:Chronic Disease; D003925:Diabetic Angiopathies / Q000188:drug therapy / Q000209:etiology* / Q000473:pathology; D004730:Endothelium, Vascular / Q000737:chemistry; D019276:Glycocalyx / Q000737:chemistry / Q000187:drug effects / Q000502:physiology*; D006025:Glycosaminoglycans / Q000627:therapeutic use; D006801:Humans; D014652:Vascular Diseases / Q000188:drug therapy / Q000209:etiology* / Q000473:pathology; D014690:Venous Pressure / Q000502:physiology
D006025:Glycosaminoglycans; C007858:glucuronyl glucosamine glycan sulfate
Aterosclerosis; Atherosclerosis; Chronic venous disease; Disfunción endotelial; Endothelial dysfunction; Enfermedad venosa crónica; Glucocáliz; Glycocalyx; Mexico; México; Sulodexida; Sulodexide